Nearly Half of Wegovy Users Stop Within 5 Months — Cost Is the Biggest Factor | Research

The takeaway

46% of real-world semaglutide (Wegovy) users discontinued within 5 months, with higher copayments strongly associated with early dropout.

46% discontinued by month 5
Nearly half of commercially insured semaglutide users stopped treatment within 5 months, with copayment amount being the strongest predictor — rates rose from 41% to 51% across copay quintiles.

What the researchers found

Among 15,811 commercially insured adults who started semaglutide for weight management, 46% discontinued within the first 5 months. Discontinuation was strongly linked to out-of-pocket costs: rates ranged from 41% in the lowest copayment quintile ($1-$54/month) to 51% in the highest quintile ($161-$1,460/month). Most users deviated from the recommended monthly dose-escalation schedule. Similar discontinuation rates (48%) were observed in patients starting after supply shortages resolved (post-October 2023), indicating the problem is not supply-driven.

Why it matters

GLP-1 peptide drugs like semaglutide require ongoing use to maintain weight loss — stopping typically leads to weight regain. With nearly half of real-world users quitting within 5 months, the actual public health impact of these drugs may be far less than clinical trial results suggest. The strong association with cost highlights that access, not just efficacy, is the critical challenge for peptide-based obesity therapies.

How the study worked

Retrospective cohort study using insurance claims data for 15,811 commercially insured US adults who initiated semaglutide for weight management (single-dose prefilled pens) between June 2021 and December 2023. Dose-titration patterns were tracked over 5 months. Multivariable Cox regression identified factors associated with discontinuation. Sensitivity analyses examined patterns after supply shortage resolution.

What this study cannot tell us

The study used insurance claims data, which cannot capture reasons for discontinuation beyond cost (e.g., side effects, inadequate response, personal choice). It included only commercially insured adults, so patterns may differ for Medicare, Medicaid, or uninsured populations. The 5-month follow-up is relatively short for a chronic therapy. Dose-titration deviations could reflect supply shortages during part of the study period, though sensitivity analysis after shortage resolution showed similar patterns.

How to read the evidence

This is a large retrospective cohort study using real-world insurance claims data from over 15,000 patients. While it provides strong evidence about prescribing patterns and discontinuation, it cannot establish causation for why patients stop treatment.

When this study was published

Published in 2025 using data through December 2023, this study captures the early real-world experience with Wegovy during a period of both supply shortages and rapidly growing demand.

The bigger picture

The GLP-1 peptide drug revolution has produced impressive clinical trial results, but this study reveals a stark gap between trial outcomes and real-world persistence. Cost barriers are the dominant factor driving discontinuation, raising urgent questions about health equity and the sustainability of long-term peptide-based weight management. As these drugs become central to obesity treatment guidelines, insurance coverage and pricing policies will determine whether their benefits reach the patients who need them most.

Questions still open

What proportion of discontinuation is driven by cost versus side effects versus insufficient weight loss?
Do patients who stop semaglutide experience weight regain at the rates seen in clinical withdrawal studies?
Would reducing out-of-pocket costs below a threshold significantly improve long-term adherence?

Common questions

Why do so many people stop taking Wegovy?

The study found that cost is the biggest factor — patients with higher monthly copayments were significantly more likely to quit. Other factors likely include side effects (nausea is common during dose escalation), insufficient weight loss expectations, and the burden of weekly injections. Lower income and education levels were also associated with higher discontinuation rates.

What happens when you stop taking semaglutide for weight loss?

Clinical trials have shown that most patients regain a significant portion of lost weight after stopping semaglutide, because the drug works by continuously suppressing appetite through GLP-1 receptor activation. This makes the high discontinuation rate especially concerning, as nearly half of users may not maintain whatever weight loss they achieved during the first few months.

Read the original research

Titration and discontinuation of semaglutide for weight management in commercially insured US adults.

Obesity (Silver Spring, Md.), 33(7), 1243-1248

View on PubMed ↗Publisher’s paper ↗

Citation

Xu, Yunwen; Carrero, Juan J; Chang, Alexander R; Inker, Lesley A; Zhang, Donglan; Mukhopadhyay, Amrita; Blecker, Saul B; Horwitz, Leora I; Grams, Morgan E; Shin, Jung-Im. (2025). Titration and discontinuation of semaglutide for weight management in commercially insured US adults.. Obesity (Silver Spring, Md.), 33(7), 1243-1248. https://doi.org/10.1002/oby.24315